• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human TELO2-interacting protein 2 (TTI2)

ACP15809

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP15809 Target NameTTI2
Target SynonymsC8orf41; CH041_HUMAN; TELO2 interacting protein 2provided; TTI2; Uncharacterized protein C8orf41FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-508
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ6NXR4
Background Information
  • Uniprot Id

    Q6NXR4

  • Target Species

    Human

  • Target Name

    TTI2

  • Target Full Name

    TELO2-interacting protein 2

  • Target Function

    Regulator of the DNA damage response (DDR). Part of the TTT complex that is required to stabilize protein levels of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family proteins. The TTT complex is involved in the cellular resistance to DNA damage stresses, like ionizing radiation (IR), ultraviolet (UV) and mitomycin C (MMC). Together with the TTT complex and HSP90 may participate in the proper folding of newly synthesized PIKKs.

  • Target Involvement

    Mental retardation, autosomal recessive 39 (MRT39)

  • Target Protein Families

    TTI2 family

  • Target Synonyms

    C8orf41; CH041_HUMAN; TELO2 interacting protein 2provided; TTI2; Uncharacterized protein C8orf41

Inquire Recombinant Human TELO2-interacting protein 2 (TTI2) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification